Elisabet González-Mira

Elisabet González-Mira

Auto-generated profile, based on publicly available information

Elisabet González-Mira

Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Ana Catarina SousaAna Catarina Sousa
Ana Catarina Sousa
EGE. González-Mira
E. González-Mira
MGMª Luisa García
Mª Luisa García
MEM.A. Egea
M.A. Egea
JFJ. Fonseca
J. Fonseca
DFD. Ferreira
D. Ferreira

1 December 2010 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
EGE. Gonzalez-Mira
E. Gonzalez-Mira
MEM.A. Egea
M.A. Egea
MGMª Luisa García
Mª Luisa García
Eliana B. SoutoEliana B. Souto
Eliana B. Souto

1 June 2010 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JAJ. Araújo
J. Araújo
EGE. Gonzalez-Mira
E. Gonzalez-Mira
MEM.A. Egea
M.A. Egea
MGM.L. Garcia
M.L. Garcia
Eliana B. SoutoEliana B. Souto
Eliana B. Souto

20 December 2010 in Nanotechnology
Verified
Journal Article
Closed access
EGE Gonzalez-Mira
E Gonzalez-Mira
MEM A Egea
M A Egea
Eliana B. SoutoEliana B. Souto
Eliana B. Souto
ANA CRISTINA CALPENAANA CRISTINA CALPENA
ANA CRISTINA CALPENA
MGMª Luisa García
Mª Luisa García
The purpose of this study was to design and optimize a new topical delivery system for ocular administration of flurbiprofen (FB), based on lipid nanoparticles. These particles, called nanostructured lipid carriers (NLC), were composed of a fatty acid (stearic acid (SA)) as the solid lipid and a mixture of Miglyol(®) 812 and castor oil (CO) as the liquid lipids, prepared by the hot high pressure homogenization method. After selecting the critical variables influencing the physicochemical characteristics of the NLC (the liquid lipid (i.e. oil) concentration with respect to the total lipid (cOil/L (wt%)), the surfactant and the flurbiprofen concentration, on particle size, polydispersity index and encapsulation efficiency), a three-factor five-level central rotatable composite design was employed to plan and perform the experiments. Morphological examination, crystallinity and stability studies were also performed to accomplish the optimization study. The results showed that increasing cOil/L (wt%) was followed by an enhanced tendency to produce smaller particles, but the liquid to solid lipid proportion should not exceed 30 wt% due to destabilization problems. Therefore, a 70:30 ratio of SA to oil (miglyol + CO) was selected to develop an optimal NLC formulation. The smaller particles obtained when increasing surfactant concentration led to the selection of 3.2 wt% of Tween(®) 80 (non-ionic surfactant). The positive effect of the increase in FB concentration on the encapsulation efficiency (EE) and its total solubilization in the lipid matrix led to the selection of 0.25 wt% of FB in the formulation. The optimal NLC showed an appropriate average size for ophthalmic administration (228.3 nm) with a narrow size distribution (0.156), negatively charged surface (-33.3 mV) and high EE (∼90%). The in vitro experiments proved that sustained release FB was achieved using NLC as drug carriers. Optimal NLC formulation did not show toxicity on ocular tissues.

2 July 2010 in Current Eye Research
Verified
Journal Article
Closed access
PDF file
Eliana B. SoutoEliana B. Souto
Eliana B. Souto
SDSlavomira Doktorovova
Slavomira Doktorovova
EGElisabet Gonzalez-Mira
Elisabet Gonzalez-Mira
MEMaria Antonia Egea
Maria Antonia Egea
MGMaria Luisa Garcia
Maria Luisa Garcia
Due to the multiple barriers imposed by the eye against the penetration of drugs, the ocular delivery and targeting are considered difficult to achieve. A major challenge in ocular drug therapy is to improve the poor bioavailability of topically applied ophthalmic drugs by overcoming the severe constraints imposed by the eye on drug absorption. One of the promising strategies nowadays is the use of colloidal carrier systems characterized by a submicron-meter size. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) represent promising alternatives to conventional and very popular ocular carrier systems, such as the nanoemulsions, liposomes, and polymeric nanoparticles. Nevertheless, taking into account the characteristics of the eye, morphometrical properties of the colloidal systems (e.g., average particle size and polydispersion) may represent a limiting factor for topical application without induced corneal irritation, being responsible for the selected system. This review article focuses on the application of lipid nanoparticles (SLN, NLC) as carriers for both non-steroidal and steroidal anti-inflammatory drugs for the treatment of ocular inflammatory disorders. Major benefits, as well as shortcomings, of ocular inflammation conditions are described, in particular upon management of inflammation induced by ocular surgery (e.g., cataracts, refractive surgery). Particular emphasis is given to the clinical choices currently available, while examining the most recent drugs that have been approved.